Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264019 | 0.75 | CRBN (0.46) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL2719765 | 0.71 | CRBN (0.54) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL17205220 | 0.71 | CRBN (0.38) | CRBNPKMDDB1POLBHSD17B10 | |
| SCHEMBL3993881 | 0.70 | CRBN (0.45) | CRBNDDB1DUTPOLBHSD17B10 | |
| SCHEMBL24923587 | 0.68 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL1344880 | 0.68 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL3235862 | 0.68 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL24211424 | 0.68 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL2983403 | 0.68 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB | |
| SCHEMBL27411171 | 0.68 | CRBN (0.50) | CRBNPKMDDB1DUTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| US-20240200061-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011130624-A2 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011103137-A1 | CELL-BASED METHODS AND REAGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110150894-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011005786-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005765-A1 | BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005793-A1 | CELL-BASED BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2009155504-A9 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | CRBN 233/4885PKM 4642/4885DDB1 1919/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | CRBN 3637/4885PKM 4798/4885DDB1 934/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | CRBN 3966/4885PKM 2664/4885DDB1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.